Biokine targets the CXCR4/CXCL12 axis which is critically involved in regulating stem cell mobilization and in the development and progression of cancer.
+ More
BKT140 - A potent CXCR4 antagonist with a unique stem cell mobilization activity and anti-cancer properties. Completed Phase I/IIa study in multiple myeloma patients in 2010.
Biokine is developing a series of anti inflammatory and anti-cancer agents that are in clinical ,pre-clinical and discovery phase.
September 4 2012: Biokine out-licenses BKT140, a Phase II ready Drug for stem cell mobilization and the treatment of leukemia and other hematological cancers to BioLineRx- BioLineRx Ltd.
